Skip to main content

Table 1 Baseline characteristics of patients

From: Does atorvastatin have augmentative effects with sodium valproate in prevention of migraine with aura attacks? A triple-blind controlled clinical trial

Characteristics Active (n = 33) Placebo (n = 31) P-value
Age, median 37.2 (23–57) 36.4 (22–52) 0.06
Women, No. (%) 22 (66.6) 21 (67.7) 0.82
Employment status, No. (%)
 Employed or student 21 (63.6) 24 (77.4)  
 Household 9 (27.2) 3 (9.6) 0.051
 Unemployed 3 (9) 4 (12.9)  
Body mass index, median (IQR) 18.47 (19.2–30.4) 20.67 (20.07–27.85) 0.06
Smoking status, No. (%)
 Never 20 (60) 17 (54)  
 Former 5 (15) 6 (19) 0.36
 Current 8 (24) 8 (25)  
Comorbidities, No. (%)
 Seasonal allergies 8 (24) 5 (16) 0.83
 Depression 4 (12) 2 (6)
 Anxiety 5 (15) 4 (13)
 Asthma 2 (6) 3 (9)
 Emotional stress 5 (15) 6 (19)
 Sleep problems 7 (21) 8 (25)
Duration of migraine, No. (%)
 ≤ 2 years 19 (57.6) 17 (54.8) 0.216
 > 2 years 14 (42.4) 14 (45.2)
Number of Attacks (mean ± SD) 4.67 ± 1.05 4.61 ± 1.09 0.743
Pre-treatment Median (IQR) 5 (2) 5 (1)
Pain Severity (mean ± SD) 7.85 ± 1.03 7.90 ± 0.91 0.899
Pre-treatment Median (IQR) 8 (2) 8 (2)
  1. BMI Body–mass index, SD Standard deviation, IQR Interquartile range